nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—FGFR1—breast cancer	0.0797	0.189	CbGaD
Ponatinib—FGFR2—breast cancer	0.0797	0.189	CbGaD
Ponatinib—ABL1—breast cancer	0.0561	0.133	CbGaD
Ponatinib—SRC—breast cancer	0.0508	0.121	CbGaD
Ponatinib—KDR—breast cancer	0.0477	0.113	CbGaD
Ponatinib—KIT—breast cancer	0.045	0.107	CbGaD
Ponatinib—ABCG2—breast cancer	0.0249	0.0592	CbGaD
Ponatinib—ABCB11—Tamoxifen—breast cancer	0.018	0.0674	CbGbCtD
Ponatinib—CYP2D6—breast cancer	0.0145	0.0345	CbGaD
Ponatinib—ABCB11—Paclitaxel—breast cancer	0.014	0.0525	CbGbCtD
Ponatinib—CYP3A4—breast cancer	0.0125	0.0296	CbGaD
Ponatinib—ABCB11—Vinblastine—breast cancer	0.0123	0.046	CbGbCtD
Ponatinib—ABCB1—breast cancer	0.0104	0.0246	CbGaD
Ponatinib—CYP3A5—Lapatinib—breast cancer	0.00948	0.0355	CbGbCtD
Ponatinib—CYP2C8—Lapatinib—breast cancer	0.00912	0.0341	CbGbCtD
Ponatinib—ABCG2—Tamoxifen—breast cancer	0.00857	0.0321	CbGbCtD
Ponatinib—ABCB1—Toremifene—breast cancer	0.00846	0.0317	CbGbCtD
Ponatinib—ABCG2—Mitoxantrone—breast cancer	0.00836	0.0313	CbGbCtD
Ponatinib—ABCB11—Doxorubicin—breast cancer	0.00756	0.0283	CbGbCtD
Ponatinib—CYP3A4—Exemestane—breast cancer	0.00731	0.0274	CbGbCtD
Ponatinib—CYP2C8—Raloxifene—breast cancer	0.00691	0.0259	CbGbCtD
Ponatinib—ABCG2—Paclitaxel—breast cancer	0.00667	0.025	CbGbCtD
Ponatinib—CYP2D6—Idarubicin—breast cancer	0.0066	0.0247	CbGbCtD
Ponatinib—ABCG2—Irinotecan—breast cancer	0.00658	0.0246	CbGbCtD
Ponatinib—ABCG2—Fluorouracil—breast cancer	0.00632	0.0236	CbGbCtD
Ponatinib—ABCG2—Carboplatin—breast cancer	0.00628	0.0235	CbGbCtD
Ponatinib—CYP3A4—Letrozole—breast cancer	0.00622	0.0233	CbGbCtD
Ponatinib—ABCB1—Lapatinib—breast cancer	0.00617	0.0231	CbGbCtD
Ponatinib—CYP3A4—Anastrozole—breast cancer	0.00554	0.0207	CbGbCtD
Ponatinib—CYP3A4—Toremifene—breast cancer	0.00507	0.019	CbGbCtD
Ponatinib—ABCG2—Docetaxel—breast cancer	0.00482	0.018	CbGbCtD
Ponatinib—CYP3A5—Tamoxifen—breast cancer	0.00475	0.0178	CbGbCtD
Ponatinib—CYP3A4—Fulvestrant—breast cancer	0.00471	0.0176	CbGbCtD
Ponatinib—CYP2C8—Tamoxifen—breast cancer	0.00456	0.0171	CbGbCtD
Ponatinib—CYP3A4—Thiotepa—breast cancer	0.0042	0.0157	CbGbCtD
Ponatinib—CYP3A4—Ixabepilone—breast cancer	0.00384	0.0144	CbGbCtD
Ponatinib—CYP3A4—Lapatinib—breast cancer	0.0037	0.0138	CbGbCtD
Ponatinib—CYP3A5—Paclitaxel—breast cancer	0.0037	0.0138	CbGbCtD
Ponatinib—CYP3A5—Irinotecan—breast cancer	0.00365	0.0136	CbGbCtD
Ponatinib—ABCG2—Doxorubicin—breast cancer	0.00359	0.0135	CbGbCtD
Ponatinib—CYP2C8—Paclitaxel—breast cancer	0.00355	0.0133	CbGbCtD
Ponatinib—ABCG2—Methotrexate—breast cancer	0.00348	0.013	CbGbCtD
Ponatinib—ABCB1—Vinorelbine—breast cancer	0.00342	0.0128	CbGbCtD
Ponatinib—CYP2C8—Fluorouracil—breast cancer	0.00336	0.0126	CbGbCtD
Ponatinib—CYP2D6—Vinorelbine—breast cancer	0.00323	0.0121	CbGbCtD
Ponatinib—ABCB1—Tamoxifen—breast cancer	0.00309	0.0116	CbGbCtD
Ponatinib—ABCB1—Mitoxantrone—breast cancer	0.00301	0.0113	CbGbCtD
Ponatinib—CYP2D6—Tamoxifen—breast cancer	0.00291	0.0109	CbGbCtD
Ponatinib—CYP3A4—Raloxifene—breast cancer	0.0028	0.0105	CbGbCtD
Ponatinib—CYP3A5—Docetaxel—breast cancer	0.00267	0.01	CbGbCtD
Ponatinib—ABCB1—Gemcitabine—breast cancer	0.00266	0.00996	CbGbCtD
Ponatinib—ABCB1—Paclitaxel—breast cancer	0.00241	0.009	CbGbCtD
Ponatinib—ABCB1—Irinotecan—breast cancer	0.00237	0.00888	CbGbCtD
Ponatinib—ABCB1—Vinblastine—breast cancer	0.00211	0.00789	CbGbCtD
Ponatinib—CYP3A4—Vinorelbine—breast cancer	0.00205	0.00767	CbGbCtD
Ponatinib—CYP2D6—Vinblastine—breast cancer	0.00199	0.00744	CbGbCtD
Ponatinib—CYP3A4—Tamoxifen—breast cancer	0.00185	0.00693	CbGbCtD
Ponatinib—CYP3A4—Mitoxantrone—breast cancer	0.00181	0.00676	CbGbCtD
Ponatinib—ABCB1—Docetaxel—breast cancer	0.00174	0.00651	CbGbCtD
Ponatinib—FGFR4—mammary gland—breast cancer	0.00157	0.0301	CbGeAlD
Ponatinib—CYP3A4—Paclitaxel—breast cancer	0.00144	0.00539	CbGbCtD
Ponatinib—KDR—umbilical vein—breast cancer	0.00144	0.0276	CbGeAlD
Ponatinib—CYP3A4—Irinotecan—breast cancer	0.00142	0.00532	CbGbCtD
Ponatinib—ABCB1—Doxorubicin—breast cancer	0.0013	0.00485	CbGbCtD
Ponatinib—CYP3A4—Vinblastine—breast cancer	0.00126	0.00473	CbGbCtD
Ponatinib—ABCB1—Methotrexate—breast cancer	0.00126	0.0047	CbGbCtD
Ponatinib—CYP2D6—Doxorubicin—breast cancer	0.00122	0.00457	CbGbCtD
Ponatinib—FGFR4—embryo—breast cancer	0.00107	0.0206	CbGeAlD
Ponatinib—CYP3A4—Docetaxel—breast cancer	0.00104	0.0039	CbGbCtD
Ponatinib—BCR—mammary gland—breast cancer	0.000925	0.0178	CbGeAlD
Ponatinib—CYP3A4—Doxorubicin—breast cancer	0.000777	0.00291	CbGbCtD
Ponatinib—BCR—nipple—breast cancer	0.000765	0.0147	CbGeAlD
Ponatinib—RET—mammary gland—breast cancer	0.000737	0.0142	CbGeAlD
Ponatinib—FGFR3—embryo—breast cancer	0.00073	0.014	CbGeAlD
Ponatinib—FGFR2—Estradiol—Fulvestrant—breast cancer	0.000712	0.33	CbGdCrCtD
Ponatinib—FGFR4—pituitary gland—breast cancer	0.000708	0.0136	CbGeAlD
Ponatinib—FGFR2—mammary gland—breast cancer	0.0007	0.0135	CbGeAlD
Ponatinib—Nilotinib—EPHB4—breast cancer	0.000674	0.173	CrCbGaD
Ponatinib—TEK—mammary gland—breast cancer	0.000671	0.0129	CbGeAlD
Ponatinib—FGFR4—female reproductive system—breast cancer	0.000648	0.0125	CbGeAlD
Ponatinib—FGFR4—adrenal gland—breast cancer	0.000633	0.0122	CbGeAlD
Ponatinib—LCK—nipple—breast cancer	0.000609	0.0117	CbGeAlD
Ponatinib—PDGFRA—mammary gland—breast cancer	0.000608	0.0117	CbGeAlD
Ponatinib—FGFR3—epithelium—breast cancer	0.000596	0.0115	CbGeAlD
Ponatinib—FGFR4—female gonad—breast cancer	0.00059	0.0113	CbGeAlD
Ponatinib—FGFR3—skin of body—breast cancer	0.000566	0.0109	CbGeAlD
Ponatinib—FGFR4—endocrine gland—breast cancer	0.000549	0.0106	CbGeAlD
Ponatinib—KDR—mammary gland—breast cancer	0.000549	0.0105	CbGeAlD
Ponatinib—RET—embryo—breast cancer	0.000503	0.00967	CbGeAlD
Ponatinib—KIT—mammary gland—breast cancer	0.000486	0.00935	CbGeAlD
Ponatinib—FGFR2—embryo—breast cancer	0.000478	0.00919	CbGeAlD
Ponatinib—BCR—endometrium—breast cancer	0.000462	0.00889	CbGeAlD
Ponatinib—TEK—embryo—breast cancer	0.000458	0.00881	CbGeAlD
Ponatinib—KDR—nipple—breast cancer	0.000454	0.00872	CbGeAlD
Ponatinib—Nilotinib—MAPK8—breast cancer	0.00045	0.115	CrCbGaD
Ponatinib—FGFR3—female reproductive system—breast cancer	0.000442	0.00851	CbGeAlD
Ponatinib—FGFR3—adrenal gland—breast cancer	0.000432	0.0083	CbGeAlD
Ponatinib—BCR—uterus—breast cancer	0.000426	0.00819	CbGeAlD
Ponatinib—FGFR4—Vinblastine—Vinorelbine—breast cancer	0.000426	0.197	CbGdCrCtD
Ponatinib—ABL1—mammary gland—breast cancer	0.000423	0.00814	CbGeAlD
Ponatinib—BCR—pituitary gland—breast cancer	0.000418	0.00804	CbGeAlD
Ponatinib—BCR—adipose tissue—breast cancer	0.000417	0.00801	CbGeAlD
Ponatinib—PDGFRA—embryo—breast cancer	0.000415	0.00798	CbGeAlD
Ponatinib—RET—epithelium—breast cancer	0.00041	0.00789	CbGeAlD
Ponatinib—SRC—embryo—breast cancer	0.000407	0.00783	CbGeAlD
Ponatinib—KIT—nipple—breast cancer	0.000402	0.00773	CbGeAlD
Ponatinib—FGFR2—epithelium—breast cancer	0.00039	0.0075	CbGeAlD
Ponatinib—BCR—female reproductive system—breast cancer	0.000383	0.00736	CbGeAlD
Ponatinib—FLT3—female reproductive system—breast cancer	0.00038	0.00731	CbGeAlD
Ponatinib—FGFR4—lymph node—breast cancer	0.000379	0.00729	CbGeAlD
Ponatinib—FGFR1—uterus—breast cancer	0.000379	0.00729	CbGeAlD
Ponatinib—LYN—endocrine gland—breast cancer	0.000376	0.00724	CbGeAlD
Ponatinib—FGFR3—endocrine gland—breast cancer	0.000374	0.0072	CbGeAlD
Ponatinib—KDR—embryo—breast cancer	0.000374	0.0072	CbGeAlD
Ponatinib—TEK—epithelium—breast cancer	0.000374	0.00719	CbGeAlD
Ponatinib—BCR—adrenal gland—breast cancer	0.000374	0.00718	CbGeAlD
Ponatinib—FGFR1—pituitary gland—breast cancer	0.000372	0.00716	CbGeAlD
Ponatinib—FLT3—adrenal gland—breast cancer	0.000371	0.00713	CbGeAlD
Ponatinib—FGFR2—skin of body—breast cancer	0.000371	0.00713	CbGeAlD
Ponatinib—FGFR1—adipose tissue—breast cancer	0.000371	0.00713	CbGeAlD
Ponatinib—Imatinib—NQO2—breast cancer	0.000362	0.0928	CrCbGaD
Ponatinib—BCR—bone marrow—breast cancer	0.000361	0.00695	CbGeAlD
Ponatinib—FLT3—bone marrow—breast cancer	0.000359	0.0069	CbGeAlD
Ponatinib—ABL1—nipple—breast cancer	0.00035	0.00673	CbGeAlD
Ponatinib—BCR—female gonad—breast cancer	0.000348	0.0067	CbGeAlD
Ponatinib—FLT3—female gonad—breast cancer	0.000346	0.00665	CbGeAlD
Ponatinib—LCK—uterus—breast cancer	0.000339	0.00652	CbGeAlD
Ponatinib—TEK—endometrium—breast cancer	0.000335	0.00645	CbGeAlD
Ponatinib—RET—pituitary gland—breast cancer	0.000333	0.0064	CbGeAlD
Ponatinib—FGFR1—adrenal gland—breast cancer	0.000332	0.00639	CbGeAlD
Ponatinib—SRC—epithelium—breast cancer	0.000332	0.00639	CbGeAlD
Ponatinib—KIT—embryo—breast cancer	0.000332	0.00638	CbGeAlD
Ponatinib—LCK—adipose tissue—breast cancer	0.000332	0.00638	CbGeAlD
Ponatinib—BCR—endocrine gland—breast cancer	0.000324	0.00623	CbGeAlD
Ponatinib—FGFR2—uterus—breast cancer	0.000322	0.0062	CbGeAlD
Ponatinib—FLT3—endocrine gland—breast cancer	0.000322	0.00619	CbGeAlD
Ponatinib—SRC—skin of body—breast cancer	0.000316	0.00607	CbGeAlD
Ponatinib—FGFR2—adipose tissue—breast cancer	0.000315	0.00606	CbGeAlD
Ponatinib—FGFR1—female gonad—breast cancer	0.00031	0.00596	CbGeAlD
Ponatinib—TEK—uterus—breast cancer	0.000309	0.00594	CbGeAlD
Ponatinib—KDR—epithelium—breast cancer	0.000305	0.00587	CbGeAlD
Ponatinib—TEK—pituitary gland—breast cancer	0.000303	0.00583	CbGeAlD
Ponatinib—TEK—adipose tissue—breast cancer	0.000302	0.00581	CbGeAlD
Ponatinib—RET—adrenal gland—breast cancer	0.000297	0.00572	CbGeAlD
Ponatinib—LCK—adrenal gland—breast cancer	0.000297	0.00572	CbGeAlD
Ponatinib—Nilotinib—CSF1R—breast cancer	0.000294	0.0752	CrCbGaD
Ponatinib—FGFR2—female reproductive system—breast cancer	0.00029	0.00557	CbGeAlD
Ponatinib—ABL1—embryo—breast cancer	0.000289	0.00555	CbGeAlD
Ponatinib—LCK—bone marrow—breast cancer	0.000288	0.00553	CbGeAlD
Ponatinib—FGFR2—adrenal gland—breast cancer	0.000283	0.00543	CbGeAlD
Ponatinib—PDGFRA—uterus—breast cancer	0.00028	0.00538	CbGeAlD
Ponatinib—TEK—female reproductive system—breast cancer	0.000278	0.00534	CbGeAlD
Ponatinib—LCK—female gonad—breast cancer	0.000277	0.00533	CbGeAlD
Ponatinib—CYP2C8—mammary gland—breast cancer	0.000274	0.00528	CbGeAlD
Ponatinib—KDR—endometrium—breast cancer	0.000274	0.00527	CbGeAlD
Ponatinib—PDGFRA—adipose tissue—breast cancer	0.000274	0.00526	CbGeAlD
Ponatinib—TEK—adrenal gland—breast cancer	0.000271	0.00521	CbGeAlD
Ponatinib—KIT—epithelium—breast cancer	0.000271	0.00521	CbGeAlD
Ponatinib—SRC—adipose tissue—breast cancer	0.000268	0.00516	CbGeAlD
Ponatinib—FGFR2—female gonad—breast cancer	0.000264	0.00507	CbGeAlD
Ponatinib—ABL1—Topotecan—Irinotecan—breast cancer	0.000262	0.121	CbGdCrCtD
Ponatinib—RET—endocrine gland—breast cancer	0.000258	0.00496	CbGeAlD
Ponatinib—KIT—skin of body—breast cancer	0.000257	0.00495	CbGeAlD
Ponatinib—TEK—female gonad—breast cancer	0.000253	0.00486	CbGeAlD
Ponatinib—KDR—uterus—breast cancer	0.000252	0.00485	CbGeAlD
Ponatinib—ABCB11—endocrine gland—breast cancer	0.000252	0.00484	CbGeAlD
Ponatinib—PDGFRA—female reproductive system—breast cancer	0.000252	0.00484	CbGeAlD
Ponatinib—KDR—pituitary gland—breast cancer	0.000248	0.00477	CbGeAlD
Ponatinib—KDR—adipose tissue—breast cancer	0.000247	0.00475	CbGeAlD
Ponatinib—SRC—female reproductive system—breast cancer	0.000247	0.00474	CbGeAlD
Ponatinib—PDGFRA—adrenal gland—breast cancer	0.000245	0.00472	CbGeAlD
Ponatinib—FGFR2—endocrine gland—breast cancer	0.000245	0.00471	CbGeAlD
Ponatinib—Imatinib—CSF1R—breast cancer	0.000245	0.0627	CrCbGaD
Ponatinib—KIT—endometrium—breast cancer	0.000243	0.00467	CbGeAlD
Ponatinib—SRC—adrenal gland—breast cancer	0.000241	0.00463	CbGeAlD
Ponatinib—TEK—endocrine gland—breast cancer	0.000235	0.00452	CbGeAlD
Ponatinib—PDGFRA—female gonad—breast cancer	0.000229	0.0044	CbGeAlD
Ponatinib—Nilotinib—BRAF—breast cancer	0.000228	0.0585	CrCbGaD
Ponatinib—Nilotinib—ABL1—breast cancer	0.000228	0.0585	CrCbGaD
Ponatinib—KDR—female reproductive system—breast cancer	0.000227	0.00436	CbGeAlD
Ponatinib—SRC—female gonad—breast cancer	0.000224	0.00432	CbGeAlD
Ponatinib—ABL1—skin of body—breast cancer	0.000224	0.00431	CbGeAlD
Ponatinib—BCR—lymph node—breast cancer	0.000224	0.00431	CbGeAlD
Ponatinib—KIT—uterus—breast cancer	0.000224	0.0043	CbGeAlD
Ponatinib—FLT3—lymph node—breast cancer	0.000222	0.00428	CbGeAlD
Ponatinib—KDR—adrenal gland—breast cancer	0.000221	0.00426	CbGeAlD
Ponatinib—KIT—pituitary gland—breast cancer	0.00022	0.00422	CbGeAlD
Ponatinib—KIT—adipose tissue—breast cancer	0.000219	0.00421	CbGeAlD
Ponatinib—KDR—bone marrow—breast cancer	0.000214	0.00412	CbGeAlD
Ponatinib—PDGFRA—endocrine gland—breast cancer	0.000213	0.00409	CbGeAlD
Ponatinib—ABL1—endometrium—breast cancer	0.000211	0.00406	CbGeAlD
Ponatinib—SRC—endocrine gland—breast cancer	0.000209	0.00401	CbGeAlD
Ponatinib—KDR—female gonad—breast cancer	0.000206	0.00397	CbGeAlD
Ponatinib—KIT—female reproductive system—breast cancer	0.000201	0.00387	CbGeAlD
Ponatinib—FGFR1—lymph node—breast cancer	0.000199	0.00383	CbGeAlD
Ponatinib—KIT—adrenal gland—breast cancer	0.000196	0.00377	CbGeAlD
Ponatinib—ABL1—uterus—breast cancer	0.000195	0.00374	CbGeAlD
Ponatinib—KDR—endocrine gland—breast cancer	0.000192	0.00369	CbGeAlD
Ponatinib—ABL1—pituitary gland—breast cancer	0.000191	0.00368	CbGeAlD
Ponatinib—ABL1—adipose tissue—breast cancer	0.00019	0.00366	CbGeAlD
Ponatinib—Imatinib—ABL1—breast cancer	0.00019	0.0487	CrCbGaD
Ponatinib—KIT—bone marrow—breast cancer	0.00019	0.00365	CbGeAlD
Ponatinib—Nilotinib—KIT—breast cancer	0.000183	0.0469	CrCbGaD
Ponatinib—KIT—female gonad—breast cancer	0.000183	0.00352	CbGeAlD
Ponatinib—LCK—lymph node—breast cancer	0.000178	0.00343	CbGeAlD
Ponatinib—RET—lymph node—breast cancer	0.000178	0.00343	CbGeAlD
Ponatinib—Nilotinib—CA9—breast cancer	0.000176	0.0451	CrCbGaD
Ponatinib—ABL1—female reproductive system—breast cancer	0.000175	0.00337	CbGeAlD
Ponatinib—ABL1—adrenal gland—breast cancer	0.000171	0.00329	CbGeAlD
Ponatinib—KIT—endocrine gland—breast cancer	0.00017	0.00327	CbGeAlD
Ponatinib—ABL1—bone marrow—breast cancer	0.000165	0.00318	CbGeAlD
Ponatinib—TEK—lymph node—breast cancer	0.000162	0.00312	CbGeAlD
Ponatinib—ABL1—female gonad—breast cancer	0.000159	0.00306	CbGeAlD
Ponatinib—Imatinib—KIT—breast cancer	0.000153	0.0391	CrCbGaD
Ponatinib—ABL1—endocrine gland—breast cancer	0.000148	0.00285	CbGeAlD
Ponatinib—PDGFRA—lymph node—breast cancer	0.000147	0.00283	CbGeAlD
Ponatinib—Imatinib—CA9—breast cancer	0.000147	0.0376	CrCbGaD
Ponatinib—SRC—lymph node—breast cancer	0.000144	0.00278	CbGeAlD
Ponatinib—CYP2C8—endometrium—breast cancer	0.000137	0.00264	CbGeAlD
Ponatinib—ABL1—Epirubicin—Idarubicin—breast cancer	0.000134	0.0621	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Idarubicin—breast cancer	0.000134	0.0621	CbGdCrCtD
Ponatinib—ABL1—Doxorubicin—Idarubicin—breast cancer	0.000134	0.0621	CbGdCrCtD
Ponatinib—ABCG2—endometrium—breast cancer	0.000133	0.00256	CbGeAlD
Ponatinib—KDR—lymph node—breast cancer	0.000133	0.00255	CbGeAlD
Ponatinib—CYP2C8—pituitary gland—breast cancer	0.000124	0.00239	CbGeAlD
Ponatinib—ABCG2—uterus—breast cancer	0.000123	0.00236	CbGeAlD
Ponatinib—ABCG2—pituitary gland—breast cancer	0.000121	0.00232	CbGeAlD
Ponatinib—ABCG2—adipose tissue—breast cancer	0.00012	0.00231	CbGeAlD
Ponatinib—KIT—lymph node—breast cancer	0.000118	0.00226	CbGeAlD
Ponatinib—CYP2C8—female reproductive system—breast cancer	0.000114	0.00218	CbGeAlD
Ponatinib—CYP3A5—adipose tissue—breast cancer	0.000111	0.00214	CbGeAlD
Ponatinib—ABCG2—adrenal gland—breast cancer	0.000108	0.00207	CbGeAlD
Ponatinib—ABCG2—bone marrow—breast cancer	0.000104	0.002	CbGeAlD
Ponatinib—ABL1—lymph node—breast cancer	0.000102	0.00197	CbGeAlD
Ponatinib—Nilotinib—ABCG2—breast cancer	0.000101	0.026	CrCbGaD
Ponatinib—ABCG2—female gonad—breast cancer	0.0001	0.00193	CbGeAlD
Ponatinib—CYP2C8—endocrine gland—breast cancer	9.61e-05	0.00185	CbGeAlD
Ponatinib—CYP3A5—female gonad—breast cancer	9.32e-05	0.00179	CbGeAlD
Ponatinib—ABCB1—embryo—breast cancer	8.98e-05	0.00173	CbGeAlD
Ponatinib—CYP3A5—endocrine gland—breast cancer	8.67e-05	0.00167	CbGeAlD
Ponatinib—Imatinib—ABCG2—breast cancer	8.46e-05	0.0217	CrCbGaD
Ponatinib—CYP3A4—female reproductive system—breast cancer	7.69e-05	0.00148	CbGeAlD
Ponatinib—CYP2D6—female reproductive system—breast cancer	7.57e-05	0.00146	CbGeAlD
Ponatinib—ABCB1—epithelium—breast cancer	7.33e-05	0.00141	CbGeAlD
Ponatinib—Imatinib—PTGS1—breast cancer	7.24e-05	0.0185	CrCbGaD
Ponatinib—CYP2D6—female gonad—breast cancer	6.89e-05	0.00132	CbGeAlD
Ponatinib—ABCB1—endometrium—breast cancer	6.57e-05	0.00126	CbGeAlD
Ponatinib—CYP3A4—endocrine gland—breast cancer	6.51e-05	0.00125	CbGeAlD
Ponatinib—ABCG2—lymph node—breast cancer	6.46e-05	0.00124	CbGeAlD
Ponatinib—CYP2D6—endocrine gland—breast cancer	6.4e-05	0.00123	CbGeAlD
Ponatinib—ABL1—Idarubicin—Epirubicin—breast cancer	6.15e-05	0.0285	CbGdCrCtD
Ponatinib—ABL1—Doxorubicin—Epirubicin—breast cancer	6.15e-05	0.0285	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Epirubicin—breast cancer	6.15e-05	0.0285	CbGdCrCtD
Ponatinib—ABCB1—uterus—breast cancer	6.06e-05	0.00116	CbGeAlD
Ponatinib—ABCB1—pituitary gland—breast cancer	5.95e-05	0.00114	CbGeAlD
Ponatinib—ABCB1—adipose tissue—breast cancer	5.92e-05	0.00114	CbGeAlD
Ponatinib—Nilotinib—CYP2D6—breast cancer	5.91e-05	0.0151	CrCbGaD
Ponatinib—ABL1—Idarubicin—Doxorubicin—breast cancer	5.69e-05	0.0264	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Doxorubicin—breast cancer	5.69e-05	0.0264	CbGdCrCtD
Ponatinib—ABL1—Epirubicin—Doxorubicin—breast cancer	5.69e-05	0.0264	CbGdCrCtD
Ponatinib—ABCB1—female reproductive system—breast cancer	5.44e-05	0.00105	CbGeAlD
Ponatinib—ABCB1—adrenal gland—breast cancer	5.31e-05	0.00102	CbGeAlD
Ponatinib—ABCB1—bone marrow—breast cancer	5.14e-05	0.000988	CbGeAlD
Ponatinib—Nilotinib—CYP3A4—breast cancer	5.07e-05	0.013	CrCbGaD
Ponatinib—ABCB1—female gonad—breast cancer	4.95e-05	0.000953	CbGeAlD
Ponatinib—Imatinib—CYP2D6—breast cancer	4.93e-05	0.0126	CrCbGaD
Ponatinib—ABCB1—endocrine gland—breast cancer	4.61e-05	0.000886	CbGeAlD
Ponatinib—Imatinib—CYP3A4—breast cancer	4.23e-05	0.0108	CrCbGaD
Ponatinib—Nilotinib—ABCB1—breast cancer	4.22e-05	0.0108	CrCbGaD
Ponatinib—Imatinib—ALB—breast cancer	3.69e-05	0.00945	CrCbGaD
Ponatinib—Imatinib—ABCB1—breast cancer	3.52e-05	0.00901	CrCbGaD
Ponatinib—ABCB1—lymph node—breast cancer	3.18e-05	0.000612	CbGeAlD
Ponatinib—Infestation—Doxorubicin—breast cancer	1.77e-05	0.00014	CcSEcCtD
Ponatinib—Visual impairment—Methotrexate—breast cancer	1.77e-05	0.000139	CcSEcCtD
Ponatinib—Skin disorder—Docetaxel—breast cancer	1.76e-05	0.000139	CcSEcCtD
Ponatinib—Oedema—Capecitabine—breast cancer	1.75e-05	0.000138	CcSEcCtD
Ponatinib—Gastrointestinal pain—Paclitaxel—breast cancer	1.75e-05	0.000138	CcSEcCtD
Ponatinib—Diarrhoea—Gemcitabine—breast cancer	1.74e-05	0.000138	CcSEcCtD
Ponatinib—Infection—Capecitabine—breast cancer	1.74e-05	0.000137	CcSEcCtD
Ponatinib—Neuropathy peripheral—Doxorubicin—breast cancer	1.74e-05	0.000137	CcSEcCtD
Ponatinib—Dizziness—Irinotecan—breast cancer	1.73e-05	0.000136	CcSEcCtD
Ponatinib—Haemoglobin—Epirubicin—breast cancer	1.73e-05	0.000136	CcSEcCtD
Ponatinib—Jaundice—Doxorubicin—breast cancer	1.73e-05	0.000136	CcSEcCtD
Ponatinib—Stomatitis—Doxorubicin—breast cancer	1.73e-05	0.000136	CcSEcCtD
Ponatinib—Urinary tract infection—Doxorubicin—breast cancer	1.72e-05	0.000136	CcSEcCtD
Ponatinib—Nervous system disorder—Capecitabine—breast cancer	1.72e-05	0.000135	CcSEcCtD
Ponatinib—Haemorrhage—Epirubicin—breast cancer	1.72e-05	0.000135	CcSEcCtD
Ponatinib—Eye disorder—Methotrexate—breast cancer	1.71e-05	0.000135	CcSEcCtD
Ponatinib—Diarrhoea—Fluorouracil—breast cancer	1.71e-05	0.000135	CcSEcCtD
Ponatinib—Thrombocytopenia—Capecitabine—breast cancer	1.71e-05	0.000135	CcSEcCtD
Ponatinib—Hypoaesthesia—Epirubicin—breast cancer	1.71e-05	0.000135	CcSEcCtD
Ponatinib—Cardiac disorder—Methotrexate—breast cancer	1.7e-05	0.000134	CcSEcCtD
Ponatinib—Skin disorder—Capecitabine—breast cancer	1.7e-05	0.000134	CcSEcCtD
Ponatinib—Hyperhidrosis—Capecitabine—breast cancer	1.69e-05	0.000134	CcSEcCtD
Ponatinib—Oedema peripheral—Epirubicin—breast cancer	1.69e-05	0.000133	CcSEcCtD
Ponatinib—Connective tissue disorder—Epirubicin—breast cancer	1.69e-05	0.000133	CcSEcCtD
Ponatinib—Abdominal pain—Paclitaxel—breast cancer	1.69e-05	0.000133	CcSEcCtD
Ponatinib—Body temperature increased—Paclitaxel—breast cancer	1.69e-05	0.000133	CcSEcCtD
Ponatinib—Hepatobiliary disease—Doxorubicin—breast cancer	1.67e-05	0.000132	CcSEcCtD
Ponatinib—Epistaxis—Doxorubicin—breast cancer	1.67e-05	0.000132	CcSEcCtD
Ponatinib—Angiopathy—Methotrexate—breast cancer	1.66e-05	0.000131	CcSEcCtD
Ponatinib—Vomiting—Mitoxantrone—breast cancer	1.66e-05	0.000131	CcSEcCtD
Ponatinib—Vomiting—Irinotecan—breast cancer	1.66e-05	0.000131	CcSEcCtD
Ponatinib—Dizziness—Fluorouracil—breast cancer	1.66e-05	0.000131	CcSEcCtD
Ponatinib—Visual impairment—Epirubicin—breast cancer	1.66e-05	0.000131	CcSEcCtD
Ponatinib—Mediastinal disorder—Methotrexate—breast cancer	1.65e-05	0.00013	CcSEcCtD
Ponatinib—Rash—Irinotecan—breast cancer	1.65e-05	0.00013	CcSEcCtD
Ponatinib—Rash—Mitoxantrone—breast cancer	1.65e-05	0.00013	CcSEcCtD
Ponatinib—Dermatitis—Irinotecan—breast cancer	1.65e-05	0.00013	CcSEcCtD
Ponatinib—Dermatitis—Mitoxantrone—breast cancer	1.65e-05	0.00013	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Docetaxel—breast cancer	1.65e-05	0.00013	CcSEcCtD
Ponatinib—Chills—Methotrexate—breast cancer	1.65e-05	0.00013	CcSEcCtD
Ponatinib—Headache—Mitoxantrone—breast cancer	1.64e-05	0.000129	CcSEcCtD
Ponatinib—Headache—Irinotecan—breast cancer	1.64e-05	0.000129	CcSEcCtD
Ponatinib—Insomnia—Docetaxel—breast cancer	1.64e-05	0.000129	CcSEcCtD
Ponatinib—Paraesthesia—Docetaxel—breast cancer	1.62e-05	0.000128	CcSEcCtD
Ponatinib—Alopecia—Methotrexate—breast cancer	1.62e-05	0.000128	CcSEcCtD
Ponatinib—Vomiting—Gemcitabine—breast cancer	1.62e-05	0.000128	CcSEcCtD
Ponatinib—Dyspnoea—Docetaxel—breast cancer	1.61e-05	0.000127	CcSEcCtD
Ponatinib—Mental disorder—Methotrexate—breast cancer	1.61e-05	0.000127	CcSEcCtD
Ponatinib—Rash—Gemcitabine—breast cancer	1.61e-05	0.000127	CcSEcCtD
Ponatinib—Dermatitis—Gemcitabine—breast cancer	1.61e-05	0.000127	CcSEcCtD
Ponatinib—Eye disorder—Epirubicin—breast cancer	1.6e-05	0.000127	CcSEcCtD
Ponatinib—Malnutrition—Methotrexate—breast cancer	1.6e-05	0.000126	CcSEcCtD
Ponatinib—Erythema—Methotrexate—breast cancer	1.6e-05	0.000126	CcSEcCtD
Ponatinib—Haemoglobin—Doxorubicin—breast cancer	1.6e-05	0.000126	CcSEcCtD
Ponatinib—Headache—Gemcitabine—breast cancer	1.6e-05	0.000126	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Capecitabine—breast cancer	1.6e-05	0.000126	CcSEcCtD
Ponatinib—Flushing—Epirubicin—breast cancer	1.59e-05	0.000126	CcSEcCtD
Ponatinib—Cardiac disorder—Epirubicin—breast cancer	1.59e-05	0.000126	CcSEcCtD
Ponatinib—Vomiting—Fluorouracil—breast cancer	1.59e-05	0.000126	CcSEcCtD
Ponatinib—Dyspepsia—Docetaxel—breast cancer	1.59e-05	0.000126	CcSEcCtD
Ponatinib—Haemorrhage—Doxorubicin—breast cancer	1.59e-05	0.000125	CcSEcCtD
Ponatinib—Insomnia—Capecitabine—breast cancer	1.58e-05	0.000125	CcSEcCtD
Ponatinib—Hypoaesthesia—Doxorubicin—breast cancer	1.58e-05	0.000125	CcSEcCtD
Ponatinib—Rash—Fluorouracil—breast cancer	1.58e-05	0.000125	CcSEcCtD
Ponatinib—Dermatitis—Fluorouracil—breast cancer	1.58e-05	0.000125	CcSEcCtD
Ponatinib—Paraesthesia—Capecitabine—breast cancer	1.57e-05	0.000124	CcSEcCtD
Ponatinib—Decreased appetite—Docetaxel—breast cancer	1.57e-05	0.000124	CcSEcCtD
Ponatinib—Headache—Fluorouracil—breast cancer	1.57e-05	0.000124	CcSEcCtD
Ponatinib—Oedema peripheral—Doxorubicin—breast cancer	1.57e-05	0.000123	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Docetaxel—breast cancer	1.56e-05	0.000123	CcSEcCtD
Ponatinib—Connective tissue disorder—Doxorubicin—breast cancer	1.56e-05	0.000123	CcSEcCtD
Ponatinib—Dyspnoea—Capecitabine—breast cancer	1.56e-05	0.000123	CcSEcCtD
Ponatinib—Fatigue—Docetaxel—breast cancer	1.56e-05	0.000123	CcSEcCtD
Ponatinib—Angiopathy—Epirubicin—breast cancer	1.56e-05	0.000123	CcSEcCtD
Ponatinib—Nausea—Irinotecan—breast cancer	1.55e-05	0.000123	CcSEcCtD
Ponatinib—Nausea—Mitoxantrone—breast cancer	1.55e-05	0.000123	CcSEcCtD
Ponatinib—Mediastinal disorder—Epirubicin—breast cancer	1.55e-05	0.000122	CcSEcCtD
Ponatinib—Pain—Docetaxel—breast cancer	1.55e-05	0.000122	CcSEcCtD
Ponatinib—Constipation—Docetaxel—breast cancer	1.55e-05	0.000122	CcSEcCtD
Ponatinib—Back pain—Methotrexate—breast cancer	1.55e-05	0.000122	CcSEcCtD
Ponatinib—Dyspepsia—Capecitabine—breast cancer	1.54e-05	0.000122	CcSEcCtD
Ponatinib—Chills—Epirubicin—breast cancer	1.54e-05	0.000122	CcSEcCtD
Ponatinib—Arrhythmia—Epirubicin—breast cancer	1.53e-05	0.000121	CcSEcCtD
Ponatinib—Visual impairment—Doxorubicin—breast cancer	1.53e-05	0.000121	CcSEcCtD
Ponatinib—Asthenia—Paclitaxel—breast cancer	1.53e-05	0.000121	CcSEcCtD
Ponatinib—Decreased appetite—Capecitabine—breast cancer	1.52e-05	0.00012	CcSEcCtD
Ponatinib—Alopecia—Epirubicin—breast cancer	1.52e-05	0.00012	CcSEcCtD
Ponatinib—Nausea—Gemcitabine—breast cancer	1.51e-05	0.000119	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Capecitabine—breast cancer	1.51e-05	0.000119	CcSEcCtD
Ponatinib—Fatigue—Capecitabine—breast cancer	1.51e-05	0.000119	CcSEcCtD
Ponatinib—Pruritus—Paclitaxel—breast cancer	1.51e-05	0.000119	CcSEcCtD
Ponatinib—Vision blurred—Methotrexate—breast cancer	1.51e-05	0.000119	CcSEcCtD
Ponatinib—Mental disorder—Epirubicin—breast cancer	1.5e-05	0.000119	CcSEcCtD
Ponatinib—Constipation—Capecitabine—breast cancer	1.5e-05	0.000118	CcSEcCtD
Ponatinib—Pain—Capecitabine—breast cancer	1.5e-05	0.000118	CcSEcCtD
Ponatinib—Malnutrition—Epirubicin—breast cancer	1.49e-05	0.000118	CcSEcCtD
Ponatinib—Erythema—Epirubicin—breast cancer	1.49e-05	0.000118	CcSEcCtD
Ponatinib—Nausea—Fluorouracil—breast cancer	1.49e-05	0.000117	CcSEcCtD
Ponatinib—Eye disorder—Doxorubicin—breast cancer	1.49e-05	0.000117	CcSEcCtD
Ponatinib—Gastrointestinal pain—Docetaxel—breast cancer	1.48e-05	0.000117	CcSEcCtD
Ponatinib—Anaemia—Methotrexate—breast cancer	1.48e-05	0.000116	CcSEcCtD
Ponatinib—Flushing—Doxorubicin—breast cancer	1.47e-05	0.000116	CcSEcCtD
Ponatinib—Cardiac disorder—Doxorubicin—breast cancer	1.47e-05	0.000116	CcSEcCtD
Ponatinib—Diarrhoea—Paclitaxel—breast cancer	1.46e-05	0.000115	CcSEcCtD
Ponatinib—Back pain—Epirubicin—breast cancer	1.45e-05	0.000114	CcSEcCtD
Ponatinib—Angiopathy—Doxorubicin—breast cancer	1.44e-05	0.000114	CcSEcCtD
Ponatinib—Muscle spasms—Epirubicin—breast cancer	1.44e-05	0.000113	CcSEcCtD
Ponatinib—Gastrointestinal pain—Capecitabine—breast cancer	1.43e-05	0.000113	CcSEcCtD
Ponatinib—Mediastinal disorder—Doxorubicin—breast cancer	1.43e-05	0.000113	CcSEcCtD
Ponatinib—Abdominal pain—Docetaxel—breast cancer	1.43e-05	0.000113	CcSEcCtD
Ponatinib—Body temperature increased—Docetaxel—breast cancer	1.43e-05	0.000113	CcSEcCtD
Ponatinib—Leukopenia—Methotrexate—breast cancer	1.43e-05	0.000113	CcSEcCtD
Ponatinib—Chills—Doxorubicin—breast cancer	1.43e-05	0.000112	CcSEcCtD
Ponatinib—Arrhythmia—Doxorubicin—breast cancer	1.42e-05	0.000112	CcSEcCtD
Ponatinib—Dizziness—Paclitaxel—breast cancer	1.41e-05	0.000111	CcSEcCtD
Ponatinib—Vision blurred—Epirubicin—breast cancer	1.41e-05	0.000111	CcSEcCtD
Ponatinib—Alopecia—Doxorubicin—breast cancer	1.4e-05	0.000111	CcSEcCtD
Ponatinib—Cough—Methotrexate—breast cancer	1.39e-05	0.00011	CcSEcCtD
Ponatinib—Mental disorder—Doxorubicin—breast cancer	1.39e-05	0.00011	CcSEcCtD
Ponatinib—Body temperature increased—Capecitabine—breast cancer	1.38e-05	0.000109	CcSEcCtD
Ponatinib—Abdominal pain—Capecitabine—breast cancer	1.38e-05	0.000109	CcSEcCtD
Ponatinib—Malnutrition—Doxorubicin—breast cancer	1.38e-05	0.000109	CcSEcCtD
Ponatinib—Erythema—Doxorubicin—breast cancer	1.38e-05	0.000109	CcSEcCtD
Ponatinib—Anaemia—Epirubicin—breast cancer	1.38e-05	0.000109	CcSEcCtD
Ponatinib—Arthralgia—Methotrexate—breast cancer	1.36e-05	0.000107	CcSEcCtD
Ponatinib—Myalgia—Methotrexate—breast cancer	1.36e-05	0.000107	CcSEcCtD
Ponatinib—Vomiting—Paclitaxel—breast cancer	1.36e-05	0.000107	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.35e-05	0.000107	CcSEcCtD
Ponatinib—Rash—Paclitaxel—breast cancer	1.35e-05	0.000106	CcSEcCtD
Ponatinib—Dermatitis—Paclitaxel—breast cancer	1.34e-05	0.000106	CcSEcCtD
Ponatinib—Leukopenia—Epirubicin—breast cancer	1.34e-05	0.000106	CcSEcCtD
Ponatinib—Back pain—Doxorubicin—breast cancer	1.34e-05	0.000106	CcSEcCtD
Ponatinib—Headache—Paclitaxel—breast cancer	1.34e-05	0.000105	CcSEcCtD
Ponatinib—Muscle spasms—Doxorubicin—breast cancer	1.33e-05	0.000105	CcSEcCtD
Ponatinib—Cough—Epirubicin—breast cancer	1.3e-05	0.000103	CcSEcCtD
Ponatinib—Vision blurred—Doxorubicin—breast cancer	1.3e-05	0.000103	CcSEcCtD
Ponatinib—Asthenia—Docetaxel—breast cancer	1.3e-05	0.000102	CcSEcCtD
Ponatinib—Infection—Methotrexate—breast cancer	1.3e-05	0.000102	CcSEcCtD
Ponatinib—Hypertension—Epirubicin—breast cancer	1.29e-05	0.000102	CcSEcCtD
Ponatinib—Pruritus—Docetaxel—breast cancer	1.28e-05	0.000101	CcSEcCtD
Ponatinib—Nervous system disorder—Methotrexate—breast cancer	1.28e-05	0.000101	CcSEcCtD
Ponatinib—Anaemia—Doxorubicin—breast cancer	1.28e-05	0.000101	CcSEcCtD
Ponatinib—Thrombocytopenia—Methotrexate—breast cancer	1.28e-05	0.000101	CcSEcCtD
Ponatinib—Arthralgia—Epirubicin—breast cancer	1.27e-05	0.0001	CcSEcCtD
Ponatinib—Myalgia—Epirubicin—breast cancer	1.27e-05	0.0001	CcSEcCtD
Ponatinib—Nausea—Paclitaxel—breast cancer	1.27e-05	0.0001	CcSEcCtD
Ponatinib—Skin disorder—Methotrexate—breast cancer	1.27e-05	9.99e-05	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.26e-05	9.97e-05	CcSEcCtD
Ponatinib—Hyperhidrosis—Methotrexate—breast cancer	1.26e-05	9.94e-05	CcSEcCtD
Ponatinib—Asthenia—Capecitabine—breast cancer	1.26e-05	9.91e-05	CcSEcCtD
Ponatinib—Dry mouth—Epirubicin—breast cancer	1.24e-05	9.82e-05	CcSEcCtD
Ponatinib—Pruritus—Capecitabine—breast cancer	1.24e-05	9.77e-05	CcSEcCtD
Ponatinib—Leukopenia—Doxorubicin—breast cancer	1.24e-05	9.77e-05	CcSEcCtD
Ponatinib—Diarrhoea—Docetaxel—breast cancer	1.24e-05	9.76e-05	CcSEcCtD
Ponatinib—Oedema—Epirubicin—breast cancer	1.22e-05	9.62e-05	CcSEcCtD
Ponatinib—Infection—Epirubicin—breast cancer	1.21e-05	9.56e-05	CcSEcCtD
Ponatinib—Cough—Doxorubicin—breast cancer	1.21e-05	9.52e-05	CcSEcCtD
Ponatinib—Diarrhoea—Capecitabine—breast cancer	1.2e-05	9.45e-05	CcSEcCtD
Ponatinib—Nervous system disorder—Epirubicin—breast cancer	1.2e-05	9.44e-05	CcSEcCtD
Ponatinib—Dizziness—Docetaxel—breast cancer	1.2e-05	9.44e-05	CcSEcCtD
Ponatinib—Thrombocytopenia—Epirubicin—breast cancer	1.19e-05	9.42e-05	CcSEcCtD
Ponatinib—Hypertension—Doxorubicin—breast cancer	1.19e-05	9.42e-05	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Methotrexate—breast cancer	1.19e-05	9.37e-05	CcSEcCtD
Ponatinib—Skin disorder—Epirubicin—breast cancer	1.19e-05	9.35e-05	CcSEcCtD
Ponatinib—Hyperhidrosis—Epirubicin—breast cancer	1.18e-05	9.3e-05	CcSEcCtD
Ponatinib—Insomnia—Methotrexate—breast cancer	1.18e-05	9.3e-05	CcSEcCtD
Ponatinib—Arthralgia—Doxorubicin—breast cancer	1.18e-05	9.29e-05	CcSEcCtD
Ponatinib—Myalgia—Doxorubicin—breast cancer	1.18e-05	9.29e-05	CcSEcCtD
Ponatinib—Paraesthesia—Methotrexate—breast cancer	1.17e-05	9.23e-05	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.17e-05	9.23e-05	CcSEcCtD
Ponatinib—Dyspnoea—Methotrexate—breast cancer	1.16e-05	9.17e-05	CcSEcCtD
Ponatinib—Dizziness—Capecitabine—breast cancer	1.16e-05	9.14e-05	CcSEcCtD
Ponatinib—Dry mouth—Doxorubicin—breast cancer	1.15e-05	9.09e-05	CcSEcCtD
Ponatinib—Vomiting—Docetaxel—breast cancer	1.15e-05	9.07e-05	CcSEcCtD
Ponatinib—Dyspepsia—Methotrexate—breast cancer	1.15e-05	9.05e-05	CcSEcCtD
Ponatinib—Rash—Docetaxel—breast cancer	1.14e-05	9e-05	CcSEcCtD
Ponatinib—Dermatitis—Docetaxel—breast cancer	1.14e-05	8.99e-05	CcSEcCtD
Ponatinib—Decreased appetite—Methotrexate—breast cancer	1.13e-05	8.94e-05	CcSEcCtD
Ponatinib—Headache—Docetaxel—breast cancer	1.13e-05	8.94e-05	CcSEcCtD
Ponatinib—Oedema—Doxorubicin—breast cancer	1.13e-05	8.91e-05	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Methotrexate—breast cancer	1.13e-05	8.88e-05	CcSEcCtD
Ponatinib—Fatigue—Methotrexate—breast cancer	1.12e-05	8.87e-05	CcSEcCtD
Ponatinib—Infection—Doxorubicin—breast cancer	1.12e-05	8.85e-05	CcSEcCtD
Ponatinib—Pain—Methotrexate—breast cancer	1.11e-05	8.79e-05	CcSEcCtD
Ponatinib—Vomiting—Capecitabine—breast cancer	1.11e-05	8.78e-05	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Epirubicin—breast cancer	1.11e-05	8.77e-05	CcSEcCtD
Ponatinib—Nervous system disorder—Doxorubicin—breast cancer	1.11e-05	8.73e-05	CcSEcCtD
Ponatinib—Thrombocytopenia—Doxorubicin—breast cancer	1.11e-05	8.72e-05	CcSEcCtD
Ponatinib—Rash—Capecitabine—breast cancer	1.1e-05	8.71e-05	CcSEcCtD
Ponatinib—Insomnia—Epirubicin—breast cancer	1.1e-05	8.7e-05	CcSEcCtD
Ponatinib—Dermatitis—Capecitabine—breast cancer	1.1e-05	8.7e-05	CcSEcCtD
Ponatinib—Headache—Capecitabine—breast cancer	1.1e-05	8.65e-05	CcSEcCtD
Ponatinib—Skin disorder—Doxorubicin—breast cancer	1.1e-05	8.65e-05	CcSEcCtD
Ponatinib—Paraesthesia—Epirubicin—breast cancer	1.1e-05	8.64e-05	CcSEcCtD
Ponatinib—Hyperhidrosis—Doxorubicin—breast cancer	1.09e-05	8.61e-05	CcSEcCtD
Ponatinib—Dyspnoea—Epirubicin—breast cancer	1.09e-05	8.58e-05	CcSEcCtD
Ponatinib—Nausea—Docetaxel—breast cancer	1.07e-05	8.48e-05	CcSEcCtD
Ponatinib—Dyspepsia—Epirubicin—breast cancer	1.07e-05	8.47e-05	CcSEcCtD
Ponatinib—Gastrointestinal pain—Methotrexate—breast cancer	1.07e-05	8.41e-05	CcSEcCtD
Ponatinib—Decreased appetite—Epirubicin—breast cancer	1.06e-05	8.37e-05	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Epirubicin—breast cancer	1.05e-05	8.31e-05	CcSEcCtD
Ponatinib—Fatigue—Epirubicin—breast cancer	1.05e-05	8.3e-05	CcSEcCtD
Ponatinib—Pain—Epirubicin—breast cancer	1.04e-05	8.23e-05	CcSEcCtD
Ponatinib—Constipation—Epirubicin—breast cancer	1.04e-05	8.23e-05	CcSEcCtD
Ponatinib—Nausea—Capecitabine—breast cancer	1.04e-05	8.21e-05	CcSEcCtD
Ponatinib—Abdominal pain—Methotrexate—breast cancer	1.03e-05	8.13e-05	CcSEcCtD
Ponatinib—Body temperature increased—Methotrexate—breast cancer	1.03e-05	8.13e-05	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Doxorubicin—breast cancer	1.03e-05	8.11e-05	CcSEcCtD
Ponatinib—Insomnia—Doxorubicin—breast cancer	1.02e-05	8.05e-05	CcSEcCtD
Ponatinib—Paraesthesia—Doxorubicin—breast cancer	1.01e-05	8e-05	CcSEcCtD
Ponatinib—Dyspnoea—Doxorubicin—breast cancer	1.01e-05	7.94e-05	CcSEcCtD
Ponatinib—Gastrointestinal pain—Epirubicin—breast cancer	9.98e-06	7.87e-05	CcSEcCtD
Ponatinib—Dyspepsia—Doxorubicin—breast cancer	9.94e-06	7.84e-05	CcSEcCtD
Ponatinib—Decreased appetite—Doxorubicin—breast cancer	9.81e-06	7.74e-05	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Doxorubicin—breast cancer	9.75e-06	7.69e-05	CcSEcCtD
Ponatinib—Fatigue—Doxorubicin—breast cancer	9.73e-06	7.68e-05	CcSEcCtD
Ponatinib—Pain—Doxorubicin—breast cancer	9.65e-06	7.62e-05	CcSEcCtD
Ponatinib—Constipation—Doxorubicin—breast cancer	9.65e-06	7.62e-05	CcSEcCtD
Ponatinib—Abdominal pain—Epirubicin—breast cancer	9.65e-06	7.61e-05	CcSEcCtD
Ponatinib—Body temperature increased—Epirubicin—breast cancer	9.65e-06	7.61e-05	CcSEcCtD
Ponatinib—Asthenia—Methotrexate—breast cancer	9.35e-06	7.38e-05	CcSEcCtD
Ponatinib—Gastrointestinal pain—Doxorubicin—breast cancer	9.23e-06	7.28e-05	CcSEcCtD
Ponatinib—Pruritus—Methotrexate—breast cancer	9.22e-06	7.28e-05	CcSEcCtD
Ponatinib—Abdominal pain—Doxorubicin—breast cancer	8.92e-06	7.04e-05	CcSEcCtD
Ponatinib—Body temperature increased—Doxorubicin—breast cancer	8.92e-06	7.04e-05	CcSEcCtD
Ponatinib—Diarrhoea—Methotrexate—breast cancer	8.92e-06	7.04e-05	CcSEcCtD
Ponatinib—Asthenia—Epirubicin—breast cancer	8.75e-06	6.91e-05	CcSEcCtD
Ponatinib—Pruritus—Epirubicin—breast cancer	8.63e-06	6.81e-05	CcSEcCtD
Ponatinib—Dizziness—Methotrexate—breast cancer	8.62e-06	6.8e-05	CcSEcCtD
Ponatinib—Diarrhoea—Epirubicin—breast cancer	8.35e-06	6.59e-05	CcSEcCtD
Ponatinib—Vomiting—Methotrexate—breast cancer	8.29e-06	6.54e-05	CcSEcCtD
Ponatinib—Rash—Methotrexate—breast cancer	8.22e-06	6.48e-05	CcSEcCtD
Ponatinib—Dermatitis—Methotrexate—breast cancer	8.21e-06	6.48e-05	CcSEcCtD
Ponatinib—Headache—Methotrexate—breast cancer	8.17e-06	6.44e-05	CcSEcCtD
Ponatinib—Asthenia—Doxorubicin—breast cancer	8.1e-06	6.39e-05	CcSEcCtD
Ponatinib—Dizziness—Epirubicin—breast cancer	8.07e-06	6.36e-05	CcSEcCtD
Ponatinib—Pruritus—Doxorubicin—breast cancer	7.99e-06	6.3e-05	CcSEcCtD
Ponatinib—Vomiting—Epirubicin—breast cancer	7.76e-06	6.12e-05	CcSEcCtD
Ponatinib—Nausea—Methotrexate—breast cancer	7.74e-06	6.11e-05	CcSEcCtD
Ponatinib—Diarrhoea—Doxorubicin—breast cancer	7.72e-06	6.09e-05	CcSEcCtD
Ponatinib—Rash—Epirubicin—breast cancer	7.69e-06	6.07e-05	CcSEcCtD
Ponatinib—Dermatitis—Epirubicin—breast cancer	7.69e-06	6.06e-05	CcSEcCtD
Ponatinib—Headache—Epirubicin—breast cancer	7.64e-06	6.03e-05	CcSEcCtD
Ponatinib—Dizziness—Doxorubicin—breast cancer	7.47e-06	5.89e-05	CcSEcCtD
Ponatinib—Nausea—Epirubicin—breast cancer	7.25e-06	5.72e-05	CcSEcCtD
Ponatinib—Vomiting—Doxorubicin—breast cancer	7.18e-06	5.66e-05	CcSEcCtD
Ponatinib—Rash—Doxorubicin—breast cancer	7.12e-06	5.61e-05	CcSEcCtD
Ponatinib—Dermatitis—Doxorubicin—breast cancer	7.11e-06	5.61e-05	CcSEcCtD
Ponatinib—Headache—Doxorubicin—breast cancer	7.07e-06	5.58e-05	CcSEcCtD
Ponatinib—Nausea—Doxorubicin—breast cancer	6.71e-06	5.29e-05	CcSEcCtD
Ponatinib—FGFR2—Disease—AKT1—breast cancer	4.1e-07	3.24e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IGF1—breast cancer	4.1e-07	3.24e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AKT2—breast cancer	4.1e-07	3.24e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CDKN1A—breast cancer	4.09e-07	3.23e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—MAPK3—breast cancer	4.09e-07	3.23e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GPX1—breast cancer	4.08e-07	3.23e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PTEN—breast cancer	4.08e-07	3.23e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—TYMS—breast cancer	4.07e-07	3.21e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MYC—breast cancer	4.07e-07	3.21e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TGFB1—breast cancer	4.06e-07	3.2e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EGFR—breast cancer	4.05e-07	3.2e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CYP1A1—breast cancer	4.04e-07	3.19e-06	CbGpPWpGaD
Ponatinib—KIT—Disease—AKT1—breast cancer	4.03e-07	3.18e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PLA2G4A—breast cancer	4.02e-07	3.18e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTM1—breast cancer	4.02e-07	3.18e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—NCOR1—breast cancer	4.02e-07	3.18e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ERCC2—breast cancer	4.01e-07	3.17e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MAPK8—breast cancer	4e-07	3.16e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CAV1—breast cancer	3.99e-07	3.15e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MDM2—breast cancer	3.98e-07	3.15e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EGFR—breast cancer	3.98e-07	3.14e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—KRAS—breast cancer	3.98e-07	3.14e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—MYC—breast cancer	3.97e-07	3.14e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—RAF1—breast cancer	3.97e-07	3.14e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MAPK3—breast cancer	3.97e-07	3.13e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—TGFB1—breast cancer	3.96e-07	3.13e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MAPK3—breast cancer	3.96e-07	3.13e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—RELA—breast cancer	3.95e-07	3.12e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL6—breast cancer	3.95e-07	3.12e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL6—breast cancer	3.94e-07	3.11e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CD—breast cancer	3.94e-07	3.11e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL6—breast cancer	3.93e-07	3.1e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ERBB2—breast cancer	3.93e-07	3.1e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—MAPK3—breast cancer	3.92e-07	3.09e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP17A1—breast cancer	3.91e-07	3.09e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—SERPINE1—breast cancer	3.89e-07	3.08e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—EGFR—breast cancer	3.89e-07	3.07e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTEN—breast cancer	3.88e-07	3.06e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CB—breast cancer	3.87e-07	3.06e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MTOR—breast cancer	3.87e-07	3.06e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ENO1—breast cancer	3.87e-07	3.05e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS1—breast cancer	3.87e-07	3.05e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MYC—breast cancer	3.86e-07	3.05e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GPX1—breast cancer	3.85e-07	3.04e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TGFB1—breast cancer	3.85e-07	3.04e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MYC—breast cancer	3.85e-07	3.04e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TGFB1—breast cancer	3.84e-07	3.03e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KRAS—breast cancer	3.83e-07	3.02e-06	CbGpPWpGaD
Ponatinib—FGFR1—Disease—AKT1—breast cancer	3.82e-07	3.02e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	3.81e-07	3.01e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—AKT1—breast cancer	3.81e-07	3.01e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CYP1A1—breast cancer	3.81e-07	3.01e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP2D6—breast cancer	3.79e-07	3e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—SRC—breast cancer	3.79e-07	2.99e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—STAT3—breast cancer	3.79e-07	2.99e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ERCC2—breast cancer	3.78e-07	2.99e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EGFR—breast cancer	3.77e-07	2.98e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—MTHFR—breast cancer	3.77e-07	2.98e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EGFR—breast cancer	3.76e-07	2.97e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—KRAS—breast cancer	3.76e-07	2.97e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—EGFR—breast cancer	3.73e-07	2.94e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CXCL8—breast cancer	3.72e-07	2.94e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NCOA2—breast cancer	3.72e-07	2.94e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NOS3—breast cancer	3.72e-07	2.94e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CD—breast cancer	3.69e-07	2.92e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—breast cancer	3.69e-07	2.91e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—KRAS—breast cancer	3.67e-07	2.9e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—PIK3CA—breast cancer	3.65e-07	2.89e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—STAT3—breast cancer	3.65e-07	2.89e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ALB—breast cancer	3.64e-07	2.88e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—AKT1—breast cancer	3.64e-07	2.88e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AKT1—breast cancer	3.64e-07	2.87e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CDKN1B—breast cancer	3.64e-07	2.87e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CG—breast cancer	3.64e-07	2.87e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—AKT1—breast cancer	3.62e-07	2.86e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—MAPK3—breast cancer	3.62e-07	2.86e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—FASN—breast cancer	3.61e-07	2.85e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—BCHE—breast cancer	3.59e-07	2.84e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KRAS—breast cancer	3.57e-07	2.82e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CASP3—breast cancer	3.56e-07	2.82e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL2—breast cancer	3.56e-07	2.81e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KRAS—breast cancer	3.56e-07	2.81e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—MTHFR—breast cancer	3.55e-07	2.81e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SLC5A5—breast cancer	3.55e-07	2.8e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MDM2—breast cancer	3.53e-07	2.79e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—KRAS—breast cancer	3.52e-07	2.78e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—MYC—breast cancer	3.52e-07	2.78e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PIK3CA—breast cancer	3.51e-07	2.78e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—RAF1—breast cancer	3.51e-07	2.78e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—TGFB1—breast cancer	3.51e-07	2.77e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—RELA—breast cancer	3.5e-07	2.76e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MAPK3—breast cancer	3.49e-07	2.76e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—NOS3—breast cancer	3.48e-07	2.75e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CAV1—breast cancer	3.48e-07	2.75e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ERBB2—breast cancer	3.48e-07	2.75e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCND1—breast cancer	3.47e-07	2.74e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—JUN—breast cancer	3.46e-07	2.73e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PIK3CA—breast cancer	3.45e-07	2.73e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—EGFR—breast cancer	3.44e-07	2.72e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CTNNB1—breast cancer	3.44e-07	2.71e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CB—breast cancer	3.43e-07	2.71e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MTOR—breast cancer	3.43e-07	2.71e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NQO1—breast cancer	3.43e-07	2.71e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SLC2A1—breast cancer	3.43e-07	2.71e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—breast cancer	3.4e-07	2.69e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MYC—breast cancer	3.39e-07	2.68e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TGFB1—breast cancer	3.39e-07	2.68e-06	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—AKT1—breast cancer	3.38e-07	2.67e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—HRAS—breast cancer	3.38e-07	2.67e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—PIK3CA—breast cancer	3.37e-07	2.66e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MMP9—breast cancer	3.37e-07	2.66e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CDKN1A—breast cancer	3.36e-07	2.65e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PTEN—breast cancer	3.35e-07	2.65e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—breast cancer	3.34e-07	2.64e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EGFR—breast cancer	3.32e-07	2.62e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CXCL8—breast cancer	3.3e-07	2.6e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP1B1—breast cancer	3.29e-07	2.6e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CAV1—breast cancer	3.28e-07	2.59e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PIK3CA—breast cancer	3.28e-07	2.59e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MAPK8—breast cancer	3.28e-07	2.59e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PIK3CA—breast cancer	3.27e-07	2.58e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—HRAS—breast cancer	3.25e-07	2.57e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—KRAS—breast cancer	3.25e-07	2.57e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL6—breast cancer	3.24e-07	2.56e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—PIK3CA—breast cancer	3.23e-07	2.56e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HSP90AA1—breast cancer	3.22e-07	2.55e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CDKN1B—breast cancer	3.22e-07	2.54e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CB—breast cancer	3.22e-07	2.54e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CD—breast cancer	3.2e-07	2.52e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—HRAS—breast cancer	3.19e-07	2.52e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTGS2—breast cancer	3.19e-07	2.52e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—breast cancer	3.17e-07	2.5e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CG—breast cancer	3.17e-07	2.5e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—breast cancer	3.16e-07	2.5e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ALB—breast cancer	3.16e-07	2.49e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CASP3—breast cancer	3.15e-07	2.49e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL2—breast cancer	3.15e-07	2.49e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KRAS—breast cancer	3.14e-07	2.48e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NCOA1—breast cancer	3.14e-07	2.48e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—HRAS—breast cancer	3.12e-07	2.47e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL6—breast cancer	3.11e-07	2.46e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SRC—breast cancer	3.1e-07	2.45e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—STK11—breast cancer	3.09e-07	2.44e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP19A1—breast cancer	3.09e-07	2.44e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCND1—breast cancer	3.07e-07	2.43e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—JUN—breast cancer	3.06e-07	2.42e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL6—breast cancer	3.06e-07	2.41e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CTNNB1—breast cancer	3.04e-07	2.4e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—HRAS—breast cancer	3.03e-07	2.39e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—breast cancer	3.02e-07	2.39e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—HRAS—breast cancer	3.02e-07	2.39e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—NOS3—breast cancer	3.02e-07	2.38e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—STAT3—breast cancer	2.99e-07	2.37e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—HRAS—breast cancer	2.99e-07	2.36e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—IL6—breast cancer	2.99e-07	2.36e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—PIK3CA—breast cancer	2.99e-07	2.36e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CG—breast cancer	2.98e-07	2.36e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—AKT1—breast cancer	2.98e-07	2.36e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MMP9—breast cancer	2.98e-07	2.36e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CDKN1A—breast cancer	2.97e-07	2.35e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PTEN—breast cancer	2.96e-07	2.34e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL6—breast cancer	2.9e-07	2.29e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAPK8—breast cancer	2.9e-07	2.29e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL6—breast cancer	2.89e-07	2.29e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PIK3CA—breast cancer	2.88e-07	2.28e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—COMT—breast cancer	2.87e-07	2.27e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AKT1—breast cancer	2.87e-07	2.27e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL6—breast cancer	2.86e-07	2.26e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MAPK3—breast cancer	2.86e-07	2.26e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTP1—breast cancer	2.86e-07	2.26e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HMOX1—breast cancer	2.82e-07	2.23e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AKT1—breast cancer	2.82e-07	2.23e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ITPR1—breast cancer	2.81e-07	2.22e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—breast cancer	2.79e-07	2.2e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CB—breast cancer	2.79e-07	2.2e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CD—breast cancer	2.78e-07	2.2e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MYC—breast cancer	2.78e-07	2.2e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTEN—breast cancer	2.78e-07	2.2e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TGFB1—breast cancer	2.78e-07	2.19e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—HRAS—breast cancer	2.76e-07	2.18e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTGS2—breast cancer	2.76e-07	2.18e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—AKT1—breast cancer	2.76e-07	2.18e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ALB—breast cancer	2.75e-07	2.17e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PIK3CA—breast cancer	2.74e-07	2.16e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EGFR—breast cancer	2.72e-07	2.15e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ABCB1—breast cancer	2.71e-07	2.14e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—breast cancer	2.68e-07	2.12e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AKT1—breast cancer	2.68e-07	2.11e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AKT1—breast cancer	2.67e-07	2.11e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HRAS—breast cancer	2.67e-07	2.11e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TYMS—breast cancer	2.66e-07	2.1e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—STAT3—breast cancer	2.65e-07	2.09e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—IL6—breast cancer	2.64e-07	2.09e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—AKT1—breast cancer	2.64e-07	2.09e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—NOS3—breast cancer	2.63e-07	2.08e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NCOR1—breast cancer	2.63e-07	2.08e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PLA2G4A—breast cancer	2.63e-07	2.08e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTM1—breast cancer	2.63e-07	2.08e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CD—breast cancer	2.62e-07	2.07e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ALB—breast cancer	2.59e-07	2.05e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KRAS—breast cancer	2.57e-07	2.03e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL6—breast cancer	2.55e-07	2.02e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAPK3—breast cancer	2.53e-07	2e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GPX1—breast cancer	2.52e-07	1.99e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP1A1—breast cancer	2.49e-07	1.97e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—NOS3—breast cancer	2.48e-07	1.96e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ERCC2—breast cancer	2.47e-07	1.95e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MYC—breast cancer	2.46e-07	1.95e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TGFB1—breast cancer	2.46e-07	1.94e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—AKT1—breast cancer	2.44e-07	1.93e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CB—breast cancer	2.43e-07	1.92e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EGFR—breast cancer	2.41e-07	1.9e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTEN—breast cancer	2.41e-07	1.9e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS2—breast cancer	2.4e-07	1.9e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CA—breast cancer	2.36e-07	1.87e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AKT1—breast cancer	2.35e-07	1.86e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—MTHFR—breast cancer	2.32e-07	1.83e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CB—breast cancer	2.29e-07	1.81e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—breast cancer	2.29e-07	1.81e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KRAS—breast cancer	2.28e-07	1.8e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS2—breast cancer	2.27e-07	1.79e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—AKT1—breast cancer	2.24e-07	1.77e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HRAS—breast cancer	2.19e-07	1.73e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CAV1—breast cancer	2.14e-07	1.69e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTEN—breast cancer	2.1e-07	1.66e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6—breast cancer	2.09e-07	1.65e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CA—breast cancer	2.09e-07	1.65e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—breast cancer	2.02e-07	1.6e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTEN—breast cancer	1.98e-07	1.56e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CA—breast cancer	1.96e-07	1.55e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CG—breast cancer	1.95e-07	1.54e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HRAS—breast cancer	1.93e-07	1.53e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AKT1—breast cancer	1.93e-07	1.52e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6—breast cancer	1.85e-07	1.46e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CD—breast cancer	1.72e-07	1.36e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AKT1—breast cancer	1.71e-07	1.35e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CA—breast cancer	1.7e-07	1.34e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ALB—breast cancer	1.69e-07	1.34e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NOS3—breast cancer	1.62e-07	1.28e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AKT1—breast cancer	1.6e-07	1.27e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CB—breast cancer	1.5e-07	1.18e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS2—breast cancer	1.48e-07	1.17e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CA—breast cancer	1.48e-07	1.17e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CA—breast cancer	1.39e-07	1.1e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AKT1—breast cancer	1.39e-07	1.1e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTEN—breast cancer	1.29e-07	1.02e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AKT1—breast cancer	1.21e-07	9.55e-07	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AKT1—breast cancer	1.14e-07	9e-07	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CA—breast cancer	9.12e-08	7.2e-07	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKT1—breast cancer	7.45e-08	5.88e-07	CbGpPWpGaD
